<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478192</url>
  </required_header>
  <id_info>
    <org_study_id>087-CL-088</org_study_id>
    <nct_id>NCT00478192</nct_id>
  </id_info>
  <brief_title>Study of Efficacy &amp; Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia</brief_title>
  <official_title>A Phase IIIb, Randomized, Double-Blind, Parallel Group, Multi-Center, Study to Assess the Efficacy and Safety of Multiple 30 Minute Infusions of YM087 (Conivaptan) in Subjects With Euvolemic or Hypervolemic Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the efficacy and safety of multiple infusions of conivaptan
      in subjects with euvolemic or hypervolemic hyponatremia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.</measure>
    <time_frame>Baseline and 48 hours</time_frame>
    <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Hour 48 - Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment</measure>
    <time_frame>Baseline, Hour 4, Hour 12, Hour 16, Hour 24, Hour 28, Hour 36, Hour 40 and Hour 48</time_frame>
    <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From the First Dose of Study Medication to a Confirmed &gt;4 mEq/L Increase From Baseline in Serum Sodium</measure>
    <time_frame>48 Hours</time_frame>
    <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
The endpoint was not evaluable in the placebo arm (median and interquartile range cannot be estimated) or the conivaptan QD arm (interquartile range cannot be estimated) because too high a percentage of patients were censored for the event. Only the conivaptan BID arm will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Confirmed Serum Sodium Level &gt; 4 mEq/L Increase From Baseline Over 0 to 48 Hours</measure>
    <time_frame>48 Hours</time_frame>
    <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Confirmed Serum Sodium Level Increase &gt;6 mEq/L From Baseline or Confirmed Normal Serum Sodium Level (&gt;135 mEq/L) Over the Duration 0 to 48 Hours</measure>
    <time_frame>48 Hours</time_frame>
    <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;6 mEq/L or two consecutive measurements &gt;135 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline -Adjusted Area Under the Curve (AUC) in Serum Sodium Over the Duration 0 to 48 Hours</measure>
    <time_frame>48 Hours</time_frame>
    <description>Each individual subject's change from baseline serum sodium levels was used to calculate baseline adjusted area under the curve serum sodium levels for a duration of Time 0 to Time t in hours (labeled as AUC(Na)(0-t). The last available serum sodium level prior to dosing on Day 1 was used as baseline.
&quot;t&quot;=48 Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Effective Water Clearance (EWC) at Each Time Point Through the 48-hour Assessment</measure>
    <time_frame>Baseline, Hour 12, Hour 24,Hour 36 and Hour 48</time_frame>
    <description>Effective water clearence (EWC) was calculated as EWC=V(1-(Una+Uk)/(Pna+Pk)), where V is urine volume, Una is the urine sodium concentration, Uk is the urine potassium concentration, Pna is the serum/plasma sodium concentration, an Pk is the serum /plasma potassium concentration.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Water Clearance (FWC) at Each Time Point Through the 48-hour Assessment</measure>
    <time_frame>Baseline, Hour 24 and Hour 48</time_frame>
    <description>Free water clearance (FWC) was calculated as FWC=V(1-Uosm/Posm), where V is urine volume, Uosm is the urine osmolality, Posm is the plasma sodium osmolality.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point - Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Regimen 1 Conivaptan QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg conivaptan once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2 Conivaptan BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg conivaptan two times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan</intervention_name>
    <description>premix bag</description>
    <arm_group_label>Regimen 1 Conivaptan QD</arm_group_label>
    <arm_group_label>Regimen 2 Conivaptan BID</arm_group_label>
    <other_name>YM087</other_name>
    <other_name>Vaprisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>premix bag</description>
    <arm_group_label>Regimen 3 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Euvolemic or hypervolemic (edematous) based on clinical presentation

          -  Serum sodium between 115 and 130mEq/L at baseline

        Exclusion Criteria:

          -  Clinical presentation of volume depletion or dehydration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Art Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indore</city>
        <zip>452014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnal</city>
        <zip>132001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Visakhapatnam</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astellas.us/docs/vaprisol.pdf</url>
    <description>Link to Prescribing Information</description>
  </link>
  <reference>
    <citation>Koren MJ, Hamad A, Klasen S, Abeyratne A, McNutt BE, Kalra S. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. Am J Health Syst Pharm. 2011 May 1;68(9):818-27. doi: 10.2146/ajhp100260. Erratum in: Am J Health Syst Pharm. 2011 Aug 1;68(15):1374.</citation>
    <PMID>21515866</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>March 31, 2010</results_first_submitted>
  <results_first_submitted_qc>March 31, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2010</results_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyponatremia</keyword>
  <keyword>hypervolemic</keyword>
  <keyword>euvolemic</keyword>
  <keyword>edematous</keyword>
  <keyword>conivaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient in the Placebo arm discontinued prior to dosing and therefore was not included in the Full Analysis Set (FAS) or the Safety Analysis Set (SAF).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Regimen 1 Conivaptan QD</title>
          <description>20 mg conivaptan once a day</description>
        </group>
        <group group_id="P2">
          <title>Regimen 2 Conivaptan BID</title>
          <description>20 mg conivaptan two times a day</description>
        </group>
        <group group_id="P3">
          <title>Regimen 3 Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set / Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regimen 1 Conivaptan QD</title>
          <description>20 mg conivaptan once a day</description>
        </group>
        <group group_id="B2">
          <title>Regimen 2 Conivaptan BID</title>
          <description>20 mg conivaptan two times a day</description>
        </group>
        <group group_id="B3">
          <title>Regimen 3 Placebo</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Population is Safety Analysis Set: All randomized patients who received at least one dose of study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="17.36"/>
                    <measurement group_id="B2" value="67.5" spread="14.70"/>
                    <measurement group_id="B3" value="61.8" spread="20.19"/>
                    <measurement group_id="B4" value="62.8" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Population is Safety Analysis Set: All randomized patients who received at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Population is Safety Analysis Set: All randomized patients who received at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.</title>
        <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Hour 48 - Baseline.</description>
        <time_frame>Baseline and 48 hours</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.</title>
          <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Hour 48 - Baseline.</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N= 20; 20; 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.03" spread="4.017"/>
                    <measurement group_id="O2" value="126.39" spread="3.581"/>
                    <measurement group_id="O3" value="125.55" spread="3.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48 (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.4" spread="5.21"/>
                    <measurement group_id="O2" value="133.4" spread="4.82"/>
                    <measurement group_id="O3" value="127.6" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.80"/>
                    <measurement group_id="O2" value="7.36" spread="4.04"/>
                    <measurement group_id="O3" value="1.16" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to &quot;Change from Baseline&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-Values are not adjusted on the basis of multiple comparrisons</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to &quot;Change from Baseline&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-Values are not adjusted on the basis of multiple comparrisons</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to &quot;Change from Baseline&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Values are not adjusted on the basis of multiple comparrisons</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment</title>
        <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point - Baseline</description>
        <time_frame>Baseline, Hour 4, Hour 12, Hour 16, Hour 24, Hour 28, Hour 36, Hour 40 and Hour 48</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment</title>
          <description>Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point - Baseline</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=20; 20; 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.03" spread="4.02"/>
                    <measurement group_id="O2" value="126.39" spread="3.58"/>
                    <measurement group_id="O3" value="125.55" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4 (N=19; 20; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.03" spread="4.62"/>
                    <measurement group_id="O2" value="128.47" spread="4.21"/>
                    <measurement group_id="O3" value="125.80" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 4 (N=19; 20; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="2.32"/>
                    <measurement group_id="O2" value="2.08" spread="2.65"/>
                    <measurement group_id="O3" value="-0.63" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12 (N=19; 19; 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.22" spread="5.27"/>
                    <measurement group_id="O2" value="130.85" spread="5.88"/>
                    <measurement group_id="O3" value="127.21" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 12 (N=19; 19; 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="3.44"/>
                    <measurement group_id="O2" value="4.65" spread="4.06"/>
                    <measurement group_id="O3" value="0.73" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16 (N=19; 17; 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.34" spread="4.51"/>
                    <measurement group_id="O2" value="131.04" spread="5.07"/>
                    <measurement group_id="O3" value="127.57" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 16 (N=19; 17; 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="3.46"/>
                    <measurement group_id="O2" value="4.93" spread="3.28"/>
                    <measurement group_id="O3" value="1.09" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24 (N=18; 16; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.87" spread="4.73"/>
                    <measurement group_id="O2" value="130.74" spread="5.33"/>
                    <measurement group_id="O3" value="127.48" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 24 (N=18; 16; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="3.76"/>
                    <measurement group_id="O2" value="4.62" spread="3.59"/>
                    <measurement group_id="O3" value="1.05" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 28 (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.79" spread="4.94"/>
                    <measurement group_id="O2" value="131.62" spread="4.52"/>
                    <measurement group_id="O3" value="126.49" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 28 (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="3.80"/>
                    <measurement group_id="O2" value="5.51" spread="2.75"/>
                    <measurement group_id="O3" value="0.06" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 36 (N=19; 15; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.42" spread="4.99"/>
                    <measurement group_id="O2" value="132.47" spread="5.04"/>
                    <measurement group_id="O3" value="127.31" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 36 (N=19; 15; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="3.73"/>
                    <measurement group_id="O2" value="6.54" spread="3.28"/>
                    <measurement group_id="O3" value="0.89" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 40 (N=19; 16; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.83" spread="5.04"/>
                    <measurement group_id="O2" value="132.23" spread="3.99"/>
                    <measurement group_id="O3" value="127.00" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 40 (N=19; 16; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="3.44"/>
                    <measurement group_id="O2" value="6.30" spread="3.27"/>
                    <measurement group_id="O3" value="0.58" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48 (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.44" spread="5.21"/>
                    <measurement group_id="O2" value="133.35" spread="4.82"/>
                    <measurement group_id="O3" value="127.59" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 48 (N=19; 17; 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.80"/>
                    <measurement group_id="O2" value="7.36" spread="4.04"/>
                    <measurement group_id="O3" value="1.16" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From the First Dose of Study Medication to a Confirmed &gt;4 mEq/L Increase From Baseline in Serum Sodium</title>
        <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
The endpoint was not evaluable in the placebo arm (median and interquartile range cannot be estimated) or the conivaptan QD arm (interquartile range cannot be estimated) because too high a percentage of patients were censored for the event. Only the conivaptan BID arm will be reported.</description>
        <time_frame>48 Hours</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time From the First Dose of Study Medication to a Confirmed &gt;4 mEq/L Increase From Baseline in Serum Sodium</title>
          <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
The endpoint was not evaluable in the placebo arm (median and interquartile range cannot be estimated) or the conivaptan QD arm (interquartile range cannot be estimated) because too high a percentage of patients were censored for the event. Only the conivaptan BID arm will be reported.</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.43" lower_limit="12.00" upper_limit="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Confirmed Serum Sodium Level &gt; 4 mEq/L Increase From Baseline Over 0 to 48 Hours</title>
        <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
        <time_frame>48 Hours</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Confirmed Serum Sodium Level &gt; 4 mEq/L Increase From Baseline Over 0 to 48 Hours</title>
          <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;4 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Confirmed Serum Sodium Level Increase &gt;6 mEq/L From Baseline or Confirmed Normal Serum Sodium Level (&gt;135 mEq/L) Over the Duration 0 to 48 Hours</title>
        <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;6 mEq/L or two consecutive measurements &gt;135 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
        <time_frame>48 Hours</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Confirmed Serum Sodium Level Increase &gt;6 mEq/L From Baseline or Confirmed Normal Serum Sodium Level (&gt;135 mEq/L) Over the Duration 0 to 48 Hours</title>
          <description>Confirmed sodium levels refers to two consecutive increases from baseline in sodium of &gt;6 mEq/L or two consecutive measurements &gt;135 mEq/L; baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Area Under the Curve (AUC) in Serum Sodium Over the Duration 0 to 48 Hours</title>
        <description>Each individual subject's change from baseline serum sodium levels was used to calculate baseline adjusted area under the curve serum sodium levels for a duration of Time 0 to Time t in hours (labeled as AUC(Na)(0-t). The last available serum sodium level prior to dosing on Day 1 was used as baseline.
&quot;t&quot;=48 Hours</description>
        <time_frame>48 Hours</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Area Under the Curve (AUC) in Serum Sodium Over the Duration 0 to 48 Hours</title>
          <description>Each individual subject's change from baseline serum sodium levels was used to calculate baseline adjusted area under the curve serum sodium levels for a duration of Time 0 to Time t in hours (labeled as AUC(Na)(0-t). The last available serum sodium level prior to dosing on Day 1 was used as baseline.
&quot;t&quot;=48 Hours</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.</population>
          <units>Hour * mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.72" spread="132.94"/>
                    <measurement group_id="O2" value="244.17" spread="142.64"/>
                    <measurement group_id="O3" value="23.21" spread="91.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Effective Water Clearance (EWC) at Each Time Point Through the 48-hour Assessment</title>
        <description>Effective water clearence (EWC) was calculated as EWC=V(1-(Una+Uk)/(Pna+Pk)), where V is urine volume, Una is the urine sodium concentration, Uk is the urine potassium concentration, Pna is the serum/plasma sodium concentration, an Pk is the serum /plasma potassium concentration.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point  Baseline</description>
        <time_frame>Baseline, Hour 12, Hour 24,Hour 36 and Hour 48</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Effective Water Clearance (EWC) at Each Time Point Through the 48-hour Assessment</title>
          <description>Effective water clearence (EWC) was calculated as EWC=V(1-(Una+Uk)/(Pna+Pk)), where V is urine volume, Una is the urine sodium concentration, Uk is the urine potassium concentration, Pna is the serum/plasma sodium concentration, an Pk is the serum /plasma potassium concentration.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point  Baseline</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=16; 12; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="47.91"/>
                    <measurement group_id="O2" value="39.86" spread="245.23"/>
                    <measurement group_id="O3" value="18.66" spread="45.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12 (N=14; 12; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.65" spread="684.35"/>
                    <measurement group_id="O2" value="405.21" spread="744.88"/>
                    <measurement group_id="O3" value="136.22" spread="154.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 12 (N=12;12; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.52" spread="671.78"/>
                    <measurement group_id="O2" value="365.35" spread="699.96"/>
                    <measurement group_id="O3" value="135.44" spread="123.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24 (N=14; 12; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.19" spread="794.22"/>
                    <measurement group_id="O2" value="-261.27" spread="1009.24"/>
                    <measurement group_id="O3" value="368.01" spread="688.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 24 (N=13; 11; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.61" spread="796.01"/>
                    <measurement group_id="O2" value="-391.76" spread="1206.39"/>
                    <measurement group_id="O3" value="383.73" spread="723.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 36 (N=15; 11; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.85" spread="905.18"/>
                    <measurement group_id="O2" value="12.66" spread="743.24"/>
                    <measurement group_id="O3" value="726.96" spread="1013.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 36 (N=12; 8; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-91.07" spread="912.66"/>
                    <measurement group_id="O2" value="-89.12" spread="805.36"/>
                    <measurement group_id="O3" value="810.45" spread="1079.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48 (N=14; 11; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.37" spread="1169.30"/>
                    <measurement group_id="O2" value="-179.37" spread="852.58"/>
                    <measurement group_id="O3" value="569.09" spread="1392.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 48 (N=12; 10; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.23" spread="1116.99"/>
                    <measurement group_id="O2" value="-240.39" spread="759.82"/>
                    <measurement group_id="O3" value="690.98" spread="2872.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Water Clearance (FWC) at Each Time Point Through the 48-hour Assessment</title>
        <description>Free water clearance (FWC) was calculated as FWC=V(1-Uosm/Posm), where V is urine volume, Uosm is the urine osmolality, Posm is the plasma sodium osmolality.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point  Baseline</description>
        <time_frame>Baseline, Hour 24 and Hour 48</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 Conivaptan QD</title>
            <description>20 mg conivaptan once a day</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 Conivaptan BID</title>
            <description>20 mg conivaptan two times a day</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Water Clearance (FWC) at Each Time Point Through the 48-hour Assessment</title>
          <description>Free water clearance (FWC) was calculated as FWC=V(1-Uosm/Posm), where V is urine volume, Uosm is the urine osmolality, Posm is the plasma sodium osmolality.
Baseline is the average of the two most recent serum sodium levels prior to start of dosing on day 1.
Hour 48: Hour 48 or time that ended study participation prior to the hour 48 assessment.
Change is calculated as Actual Data for each time point  Baseline</description>
          <population>Full Analysis Set (FAS): all randomized patients who received at least one dose of study drug and who had baseline serum sodium data.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=14; 11; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.87" spread="45.47"/>
                    <measurement group_id="O2" value="6.55" spread="165.07"/>
                    <measurement group_id="O3" value="-34.90" spread="74.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24 (N=14; 12; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-972.29" spread="1455.66"/>
                    <measurement group_id="O2" value="-611.14" spread="693.863"/>
                    <measurement group_id="O3" value="-416.71" spread="666.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 24 (N=11; 10; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-936.99" spread="1618.46"/>
                    <measurement group_id="O2" value="-513.33" spread="566.72"/>
                    <measurement group_id="O3" value="-420.75" spread="747.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48 (N=14;12; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1243.39" spread="2211.22"/>
                    <measurement group_id="O2" value="-769.19" spread="934.31"/>
                    <measurement group_id="O3" value="-592.96" spread="1050.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 48 (N=11; 10; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1313.98" spread="2477.39"/>
                    <measurement group_id="O2" value="-603.67" spread="761.90"/>
                    <measurement group_id="O3" value="-702.11" spread="1117.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>An Adverse Event was defined as treatment emergent if it occurred after the first dose of study drug through the ninth day after the last dose.
Participants at Risk represent the Safety Analysis Set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Regimen 1 Conivaptan QD</title>
          <description>20 mg conivaptan once a day</description>
        </group>
        <group group_id="E2">
          <title>Regimen 2 Conivaptan BID</title>
          <description>20 mg conivaptan two times a day</description>
        </group>
        <group group_id="E3">
          <title>Regimen 3 Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ventricular arrthmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyrodism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bowel sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinaise increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood presure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Heart sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a sites manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Medical Director, Medical Affairs</name_or_title>
      <organization>Astellas Pharma Global Development</organization>
      <email>clinicaltrials@us.astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

